[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genetic-predisposition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genetic-predisposition":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,49,76,113,137,173,199,226,246,272,296,324,347,379,405,427,451,478,500,522,543,564,590,623,646],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100327096","vascular-disease-discovery-protocol-100327096",false,"NCT03538639","Vascular Disease Discovery Protocol","* INCLUSION CRITERIA:\n* All subjects must be between the ages of 2-100 years old.\n* Affected pregnant women if they have been referred with a known or suspected pathology or if they become pregnant while on study.\n* Unaffected related pregnant women (including spouses\u002Fpartners) for cord blood and tissue collection (surgical waste) only at the time of delivery.\n\nEXCLUSION CRITERIA:\n\n* Healthy volunteers unable to give informed consent\n* Healthy volunteers who decline to have blood drawn and\u002For tissue studies or who do not consent to have samples stored for future research.\n* Cognitively impaired individuals who are not affected.\n* Cognitively impaired individuals not related to affected subjects.\n* Unaffected unrelated pregnant women.",true,"ALL","2 Years","100 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\nSome genetic diseases put increase the risk of heart and blood diseases, which are the number one cause of death and disability in the U.S. Researchers want to study diseases of the heart and\u002For blood vessels. They want to collect data and specimens from affected people, their family members, and healthy people.\n\nObjective:\n\nTo study diseases of the heart and\u002For blood vessels.\n\nEligibility:\n\nPeople age 2 and older who may have genetic disease affecting the heart and\u002For blood vessels Their relatives\n\nHealthy volunteers\n\nDesign:\n\nParticipants will be screened with a medical history, physical exams, and imaging tests. Participants may have a few visits or visits for 2 weeks or more. This will depend on their age and disease status. Visits may include:\n\nPhotographs of the face and body\n\nHeart tests\n\nSamples taken of blood, urine, saliva, skin, and\u002For tissue\n\nScans. For some, a dye may be injected into a vein.\n\nA six-minute walk test\n\nLung tests. For some, participants will blow into a tube. For others, they will breathe in a gas from a mask, have a small injection, then have a scan.\n\nStress tests while walking on a treadmill or riding a stationary bike\n\nUltrasound of veins and arteries\n\nDevices outside the body testing the stiffness and function of arteries\n\nEye exam and eye tests. For some, a dye may be injected in a vein.\n\nBlood pressure tests\n\nMeasurements of blood flow under the skin and in the arms and fingernail blood vessels\n\nDevices outside the body testing flexibility of the blood vessels and skin, and skin temperature",[26,27,28],"Vascular Dysfunction","Genetic Mutations","Genetic Predisposition",[30,31,32,33,34,35],"Etiology of Rare and Orphan Diseases with Vascular Phenotype","Natural History of Rare and Orphan Diseases with Vascular Phenotype","Pathophysiology of Uncommon Vascular Diseases","Undiagnosed Diseases","Rare Human Diseases with Vascular Features","Natural History","RECRUITING","2026-06-24",{"date":39,"type":40},"2026-06-25","ACTUAL",{"date":42,"type":40},"2018-07-30",{"date":44,"type":22},"2037-05-15",{"name":46,"class":47},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100436960","pancreatic-cancer-early-detection-consortium-100436960","NCT04970056","Pancreatic Cancer Early Detection Consortium","PRECEDE","Inclusion Criteria:\n\nIndividuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:\n\nCohort 1\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.\n2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+\n5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+\n6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+\n\nCohort 2\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+\n2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family\n3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member\n\nCohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)\n\nCohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.\n\nCohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and\u002For buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.\n\nCohort 6a\n\nIndividuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n\nCohort 6b\n\nIndividuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n3. Diagnosed ≤ age 45\n\nCohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.\n\nCohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.\n\nCyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)\n\nExclusion Criteria:\n\n* Individuals not meeting the criteria above.","18 Years","90 Years",{"count":59,"type":22},20000,"The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and\u002For individuals carrying pathogenic\u002Flikely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.",[62,63,64,28],"Pancreas Cancer","Pancreas Cyst","Pancreatic Ductal Adenocarcinoma","2026-06-23",{"date":67,"type":40},"2026-06-26",{"date":69,"type":40},"2020-09-18",{"date":71,"type":22},"2030-12-31",{"name":73,"class":74},"Arbor Research Collaborative for Health","OTHER",60,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":100,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100558681","phase-1-pharmacogenomic-contributions-to-trihexyphenidyl-biotransformation-and-response-in-children-with-dystonic-cerebral-palsy-100558681","NCT06554288","Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy","Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy","TRIKE2","Inclusion Criteria:\n\n* Ages 5-17 years of age\n* Diagnosis of cerebral palsy and dystonia causing interference\n* Parent\u002Flegal guardian of a child with a diagnosis of cerebral palsy and dystonia\n* Parent\u002Flegal guardian is willing and able to provide informed permission\u002Fassent for the study\n\nExclusion Criteria:\n\n* Previously or currently taking trihexyphenidyl\n* Patients turning 18 years of age within the study period (16 weeks from Study Day 1)\n* A language barrier for the patient that precludes communication and\u002For the ability to complete study-related requirements","5 Years","17 Years",{"count":87,"type":22},40,"INTERVENTIONAL",[90],"PHASE1","This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.",[93,28,94,95,96,97,98,99],"Pediatric Disorder","Dystonia, Secondary","Dystonia","Cerebral Palsy, Dystonic-Rigid","Cerebral Palsy, Dyskinetic","Trihexyphenidyl Adverse Reaction","Pharmacogenomic Drug Interaction",[101,102,95,103,104],"Pediatric","Cerebral Palsy","Pharmacogenomics","Trihexyphenidyl","2026-06-19",{"date":37,"type":40},{"date":108,"type":40},"2024-10-15",{"date":110,"type":22},"2029-12-31",{"name":112,"class":74},"Children's Mercy Hospital Kansas City",{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":135,"locationsCount":48},"100628074","outcomes-of-health-care-transition-for-aya-with-a-cancer-predisposition-100628074","NCT07456904","Outcomes of Health Care Transition for AYA With a Cancer Predisposition","OnTRAC","Inclusion Criteria:\n\n* Participants are ≥18 years of age\n* Participants with a molecular or clinical diagnosis of a Cancer Predisposition Syndrome (CPS) who are graduating or have graduated from SJCRH.\n* Participants who were a patient of the SJCRH Cancer Predisposition Clinic for at least 3 years before graduating from SJCRH\n* Participants who require cancer\u002Ftumor surveillance within 1 year after graduation from SJCRH. Required cancer\u002Ftumor surveillance in adulthood is defined as having a CPS with expert guidelines recommending cancer\u002Ftumor surveillance in adulthood\n* Participants fluent in English.\n\nExclusion Criteria:\n\n* Participants who are not their own legal medical decision-maker.",{"count":121,"type":22},56,"This observational study evaluates whether adolescents and young adults (AYAs) with a cancer predisposition syndrome (CPS) establish and maintain adult health care and continue CPS-specific cancer surveillance after graduating from pediatric care at St. Jude Children's Research Hospital (SJCRH). Participants will complete a Readiness Assessment and periodic surveys over 8 years post-graduation.\n\nPrimary Objectives\n\n* To evaluate whether adolescents and young adults (AYAs) with a cancer predisposition syndrome (CPS) report they have established care with adult health care providers and pursue CPS-specific cancer surveillance within 1-year post-graduation from SJCRH.\n* To evaluate whether AYAs with CPS report they maintain care with adult health care providers and continue CPS-specific cancer surveillance 3 years post-graduation from SJCRH.\n\nExploratory Objectives:\n\n* To evaluate whether AYAs with CPS report they continue to maintain care with adult health care providers and complete CPS-specific cancer surveillance longitudinally 5 years and 8 years post-graduation from St. Jude Children's Research Hospital (SJCRH).\n* To examine clinical correlates of establishing care with adult providers and initiating CPS-specific cancer surveillance post-graduation from SJCRH.\n* To identify the tumors diagnosed in AYAs with CPS after they graduate from SJCRH and determine how these tumors were identified (i.e., through specific surveillance tests or based on symptoms).\n* To identify barriers and facilitators AYAs face when establishing and maintaining adult health care and pursuing CPS-specific cancer surveillance.",[28],[125,126,127,128],"Genetic cancer risk","Cancer predisposition","Health care transition","Adolescent and young adult oncology","2026-06-16",{"date":131,"type":40},"2026-06-18",{"date":129,"type":40},{"date":134,"type":22},"2037-11",{"name":136,"class":74},"St. Jude Children's Research Hospital",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":88,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100185446","cosegregation-of-variants-in-panel-of-genes-100185446","NCT01689584","COsegregation of VARiants in Panel of Genes","Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling","COVAR","Inclusion Criteria:\n\nIndex cases:\n\n* A person carrying a variant of interest in a gene analyzed in a diagnostic setting by one of the laboratories within the Genetics and Cancer Group (GGC)-Unicancer network, classified as class 3, 4 or hypomorphic class 5, and selected by the national expert group for the gene concerned.\n* Age ≥ 18 years.\n* Signed written inform consent \"index case\"\n\nRelated parties:\n\n* Any relative of an index case with cancer\n* Any relative without cancer related to an index case, selected by the investigators, according to family structure and degree of related compared to the index case\n* For class 4 and hypomorphic class 5 variants; relatives currently undergoing analysis or having already obtained a test result for the variant of interest as part of clinical care.\n* Age ≥ 18 years\n* Information and signature of the informed consent \"selected relatives\"\n\nExclusion Criteria:\n\n* Minors\n* Persons deprived of liberty or under guardianship (including curators).\n* Absence of signed written inform consent",{"count":146,"type":22},11000,[148],"NA","The aim of the COVAR project is to achieve reliable classification of as many variants of interest as possible from the French OncoGenetics Database (FrOG, https:\u002F\u002Ffrog-db.fr\u002F) in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some cases to propose a prophylactic surgery.",[151,28],"Gene Mutation-Related Cancer",[153,154,155,156,157,158,159,160,161,162],"BRCA1","BRCA2","VUS","co-segregation","genetic counseling","PALB2","panel of genes","variant","hypomorphic","Hereditary cancer (breast, ovarian, prostate, pancreas, digestive track)","2026-05-22",{"date":165,"type":40},"2026-05-27",{"date":167,"type":40},"2012-07-02",{"date":169,"type":22},"2038-01-02",{"name":171,"class":74},"Institut Curie",62,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":88,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":4},"100629712","the-preventive-risk-outreach-and-cascade-testing-100629712","NCT07478237","The Preventive Risk Outreach And Cascade Testing","The Preventive Risk Outreach and Cascade Testing (PROACT)","PROACT","Inclusion Criteria - Probands\n\n1. Age ≥ 18 years old.\n2. Known to carry a pathogenic or likely pathogenic variant in a gene included in the 2024 current Color Health Cancer Panel Test.\n3. Have at least one (1) first- or second-degree relative who is living in the United States and has not yet had germline genetic testing.\n\nExclusion Criteria - Probands\n\n1\\. Unable to read and write English or Spanish.\n\nInclusion Criteria - Relatives\n\n1. Age ≥ 18 years old.\n2. Resides in the United States.\n\nExclusion Criteria - Relatives\n\n1. Completed genetic testing by a clinician within the last 5 years that included the pathogenic or likely pathogenic variant.\n2. Not a first- or second-degree relative of the proband.",{"count":182,"type":22},400,[148],"The goal of this clinical trial is to learn whether a new online program developed by the research team is able to help families learn about family cancer risk and how to reduce this risk, as well as help interested family members get low-cost, at-home genetic testing for cancer risk.",[28,186],"Family Members",[188],"Cascade genetic testing","NOT_YET_RECRUITING","2026-05-11",{"date":192,"type":40},"2026-05-14",{"date":194,"type":22},"2026-06",{"date":196,"type":22},"2029-12",{"name":198,"class":74},"Stanford University",{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":48},"100418680","diagnostic-value-of-exome-genome-sequencing-conventional-methods-in-rare-diseases-and-familial-tumor-syndromes-100418680","NCT04731857","Diagnostic Value of Exome\u002F Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes","Diagnostic Value of Exome and Genome Sequencing as Well as Conventional Methods in Rare Diseases and Familial Tumor Syndromes","EXGEFATU","Inclusion Criteria:\n\n* Patient with genetic disease or\n* Family members\n* Genetic analysis between 10\u002F2016 and 12\u002F2020 at the Institute for Medical Genetics and Applied Genomics at the University Hospital Tübingen\n\nExclusion Criteria:\n\n\\- None",{"count":208,"type":22},12000,"For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10\u002F2016 and 12\u002F2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.",[211,28],"Rare Diseases",[211,28,213,214,215,216],"Next Generation Sequencing (NGS)","Polygenic risk scores (PRSs)","Repeat-Expansion","Genetic variation","2026-04-28",{"date":219,"type":40},"2026-05-04",{"date":221,"type":40},"2021-02-18",{"date":223,"type":22},"2031-02",{"name":225,"class":74},"University Hospital Tuebingen",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":48},"100504501","barriers-and-facilitators-of-parent-child-communication-in-children-with-cancer-predisposition-100504501","NCT05849155","Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition","Inclusion Criteria:\n\n* Patient aged 10 to 24 years (inclusive)\n* Patient underwent germline genetic testing with a Pathogenic\u002FLikely Pathogenic (P\u002FLP) variant in a known cancer predisposition gene that increases risk for developing cancer\n* P\u002FLP result disclosed to the patient\n* Patient has a primary caregiver willing to participate\n* Patient and participating caregiver able to speak and read English\n\nExclusion Criteria:\n\n* Patient is only a carrier of a recessive variant that does not alone increase risk for cancer\n* Inability or unwillingness of patient or participating caregiver or to give informed consent\u002Fassent\n* Participating caregiver is under the age of 18 years\n* Patient or participating caregiver has evidence of significant cognitive deficits (per medical record) that would interfere with the ability to comprehend study questions\n* Patient's medical status or condition precludes completion of study (as determined by medical team, patient, or parent)","10 Years","24 Years",{"count":235,"type":22},125,"Testing children, adolescents, and young adults (CAYA) for a genetic risk for cancer can help with early prevention and detection of cancers through regular follow-ups and medical care. After receiving genetic test results, CAYA may not accurately understand what their results mean, and parents are often unsure about talking with their CAYA about their genetic risk for cancer. By understanding how parents communicate with their CAYA, the investigators can improve future genetic education to reduce cancer risk.\n\nPrimary Objectives:\n\n* Identify qualities of parent-CAYA (child, adolescent, and young adults) communication about CAYAs' genomic cancer risk, and their association with CAYAs' psychosocial and prevention outcomes.\n* Examine the association between sociodemographic, cancer-related, and psychosocial factors and parent-CAYA communication regarding CAYAs' genomic risk for cancer.\n* Identify barriers and facilitators of parent-CAYA communication regarding CAYAs' genomic risk for cancer.",[28],"2026-04-22",{"date":240,"type":40},"2026-04-23",{"date":242,"type":40},"2023-12-12",{"date":244,"type":22},"2028-10",{"name":136,"class":74},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":88,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":48},"100497584","enhancing-information-management-for-young-adults-after-genetic-cancer-risk-testing-100497584","NCT05759143","Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing","Inclusion Criteria AIM 1:\n\n* YA Patients:\n\n  * Ages 18-39 years, inclusive.\n  * Has had previous cancer genetic testing, with a finding of a pathogenic variant or VUS; patient has previously received results from the clinical team.\n  * English-speaking and -reading.\n  * Receiving care at DFCI.\n  * Not undergoing active cancer therapy at the time of approach.\n* Clinicians:\n\n  * Cancer risk physicians (oncologists, gastroenterologists, geneticists), oncologists, nurse practitioners, physician assistants, or genetic counselors.\n  * English-speaking and -reading.\n  * Cares for YAs aged 18-39 with cancer risk syndromes.\n\nInclusion Criteria AIM 2:\n\n* YA Patients:\n\n  * Ages 18-39 years, inclusive.\n  * Has had previous cancer genetic testing, with a finding of a pathogenic variant or VUS; patient has previously received results from the clinical team.\n  * English-speaking and -reading.\n  * Receiving care at Dana-Farber Cancer Institute.\n  * Did not participate in a stakeholder interview (Aim 1).\n  * Not undergoing active cancer therapy at the time of approach.\n* Clinicians:\n\n  * Oncologists, nurse practitioners, cancer risk physicians, or genetic counselors.\n  * English-speaking and -reading.\n  * Caring for a participating YA.","39 Years",{"count":87,"type":22},[148],"This research is being done to develop the electronic platform Nest for young adults (ages 18-39) who have had prior cancer genetic testing. The platform will give patients and their clinicians access to continuously updated information about both pathogenic variants and variants of uncertain significance (VUS).\n\nThe name of the intervention used in this research study is:\n\nNest portal (electronic platform for patients and clinicians)",[257,28],"Genetic Predisposition to Disease",[257,28,259,260,155,261,262],"Genetic Testing","Cancer Risk Syndromes","Variant of Uncertain Significance","Pathogenic Variant","2026-04-21",{"date":265,"type":40},"2026-04-24",{"date":267,"type":40},"2023-05-01",{"date":269,"type":22},"2026-07-30",{"name":271,"class":74},"Dana-Farber Cancer Institute",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":88,"phases":281,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":48},"100516333","phase-4-glucose-mgh-genetic-links-understood-through-challenge-with-oral-semaglutide-exposure-at-mgh-100516333","NCT06003153","GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH","GLUCOSE-MGH","Inclusion Criteria:\n\n1. Males or non-pregnant females\n2. Ages 18-65 (inclusive)\n3. Able\u002Fwilling to give consent\n4. Span the metabolic range between normal glycemia and pre-diabetes (fasting glucose of 100-125 mg\u002FdL based on chart review of existing laboratory data)\n\nExclusion Criteria:\n\n1. Currently taking medications or intending to take medications for diabetes\n2. Currently taking medications or intending to take medications that affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones\n3. Personal history of intestinal malabsorption, bariatric surgery, celiac disease, gallbladder disease, or pancreatitis\n4. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2\n5. Estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73 m2 per the Modification of Diet in Renal Disease equation\n6. History of cirrhosis and\u002For aspartate aminotransferase or alanine aminotransferase more than 3x upper limit of normal\n7. Dietary restrictions preventing consumption of a MMTT\n8. Women who are pregnant, nursing, or at risk of becoming pregnant\n9. Participation in other interventional studies during the current study","65 Years",{"count":235,"type":22},[282],"PHASE4","The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a standardized breakfast meal at the first visit and after taking 14 doses of oral semaglutide over two weeks before the second study visit. The food (mixed meal breakfast) we will be studying is specially prepared to contain a set amount of protein, carbohydrates, and fat. The investigators hypothesize that understanding how the acute biochemical response to oral semaglutide differs by genetic variation will generate insight into drug mechanisms and type 2 diabetes pathophysiology.",[28,285,286],"Metabolic Diseases","Type 2 Diabetes","2026-04-03",{"date":289,"type":40},"2026-04-06",{"date":291,"type":40},"2024-03-12",{"date":293,"type":22},"2027-05-31",{"name":295,"class":74},"Massachusetts General Hospital",{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":88,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":323},"100373364","exome-analysis-position-in-the-strategy-of-genetic-predisposition-factors-identification-in-early-onset-cancer-100373364","NCT04141462","EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer","EX²TRICAN","Inclusion Criteria:\n\nIndex case:\n\n1. Major or minor patient\n2. Histological or cytological evidence of malignant tumor diagnosis\n3. Patient with cancer before age 40 (or before age 30 for breast cancer).\n4. Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned\n5. Patient affiliated to a social security scheme\n6. Signature of Informed Consent EXTRICAN\n7. Availability of a tumor sample if needed secondary functional studies\n8. Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents)\n9. Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person)\n\nRelated:\n\n1. Major or minor patient\n2. Histological or cytological evidence of the diagnosis of malignant tumor if\n3. Patient affiliated to a social security scheme\n4. Signing informed consent EXTRICAN\n\nExclusion Criteria:\n\nIndex and related case:\n\n1. Refusal of the patient participation\n2. Psychiatric illness and \u002F or condition of the patient compromising the understanding of the information or the realization of the study\n3. Patient under guardianship, curatorship or safeguard of justice\n4. Pregnant woman",{"count":304,"type":22},613,[148],"5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called \" gene panel \". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called \"high-throughput exome sequencing (SHD-E)\", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.",[308,28],"Cancer",[310,311,312,313,314],"genetic mutations","early sporadic or familial cancer","gene panel","exome analysis","high-throughput exome sequencing","2026-04-02",{"date":287,"type":40},{"date":318,"type":40},"2019-10-07",{"date":320,"type":22},"2028-04-07",{"name":322,"class":74},"Centre Georges Francois Leclerc",6,{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":331,"minAge":56,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":88,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":48},"100613300","phase-1-assessment-of-topical-minoxidil-on-intraoperative-flap-perfusion-and-cutaneous-flap-viability-in-breast-recon-100613300","NCT07264790","Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon","Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Reconstruction","Inclusion Criteria:\n\n1. Female sex \\> 18 years old\n2. Genetic predisposition to cancer\n3. Undergoing bilateral prophylactic mastectomy with same-day breast reconstruction\n4. Capable of giving informed consent\n\nExclusion Criteria:\n\n1. Diagnosis of breast cancer\n2. History of cancer\n3. Currently pregnant or planning to be pregnant (for women of child-bearing potential)\n4. Male sex","FEMALE",{"count":7,"type":22},[90],"The purpose of the study is to determine whether pharmacologic delay using minoxidil in patients undergoing bilateral risk reducing mastectomy with reconstruction could achieve improvement in flap perfusion and flap viability at the time of surgery. Patients will undergo randomization of their breasts to determine which breast will receive the experimental intervention and which breast will serve as the internal control (receive placebo). The experimental breast will receive the novel pharmacologic delay treatment, 5% minoxidil, while the internal control breast will receive the current standard of care, which does not include any topical application prior to surgery - a placebo control will be used.\n\nThis will be a triple-blind study, where both the participants and investigators will be blinded to which breast will receive the intervention. The patients will receive two bottles \"compound A\" and \"compound B\" with directions from the pharmacy for which compound to apply to each breast.\n\nProduct will be applied for 2 weeks prior to planned surgery. Surgery will proceed without any changes to standard practice.",[336,337,338,28],"Breast Reconstruction","Perfusion; Complications","High Risk for Breast Cancer","2026-04-01",{"date":289,"type":40},{"date":342,"type":22},"2026-04",{"date":344,"type":22},"2027-09",{"name":346,"class":74},"Duke University",{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":331,"minAge":56,"maxAge":19,"enrollmentInfo":355,"targetDuration":357,"studyType":23,"phases":4,"briefSummary":358,"conditions":359,"keywords":362,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":378},"100550044","prospective-multicenter-registry-of-gender-diversity-and-inclusion-gedi-of-women-with-acute-coronary-syndrome-100550044","NCT06441942","Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome","Creation of a Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) in Phenotypic and Genetic Characterization of Acute Coronary Syndrome.","ACS GEDI","Inclusion Criteria:\n\n* Women \\>\u002F= 18 years with ACS (STEMI, NSTEMI or Unstable Angina).\n\nExclusion Criteria:\n\n* age \\\u003C 18 years and\u002For unwillingness to sign informed consent and\u002For unwillingness to make follow-up visits",{"count":356,"type":22},100,"12 Months","Create a multicenter prospective registry that collects information from women affected by acute coronary syndrome (ACS). This registry aims to understand the diversity in the presentation of women with ACS. It proposes to conduct a thorough characterization of the women involved in the study through genetic, biochemical, and molecular analysis.This approach aims to identify any differences in the characteristics of women with ACS and to identify disease subtypes that may influence treatment options and clinical outcomes.",[360,361,28],"Acute Coronary Syndrome","Gender",[363,364,365,366,367,368,369],"ACS","GEDI","Genetic","DNA","mRNA","Proteomic","Metabolomic","2026-03-30",{"date":287,"type":40},{"date":373,"type":40},"2025-01-28",{"date":375,"type":22},"2027-02-28",{"name":377,"class":74},"IRCCS San Raffaele",4,{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":16,"sex":17,"minAge":385,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":88,"phases":389,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":48},"100590821","phase-2-the-effect-of-rs7903146-genotype-on-islet-glp-1-production-in-humans-100590821","NCT06972407","The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans","Inclusion Criteria:\n\n* Subjects with the TT or CC genotype at rs7903146\n\nExclusion Criteria:\n\n1. Age \\\u003C 25 or \\> 70 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).\n2. CT genotype at rs7903146\n3. HbA1c \\> 6.5%\n4. Use of any glucose-lowering agents including metformin or sulfonylureas.\n5. For female subjects: positive pregnancy test at the time of enrollment or study.\n6. History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.\n7. Active systemic illness or malignancy.\n8. Symptomatic macrovascular or microvascular disease.","25 Years","70 Years",{"count":388,"type":22},80,[390],"PHASE2","The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1\u002F3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. Common genetic variation in the TCF7L2 locus (T-allele at rs7903146) arguably confers the greatest genetic risk of T2DM. It is associated with α- and β-cell dysfunction. TCF7L2 (the product of TCF7L2) was first described as the transcription factor necessary for proglucagon expression in intestinal L-cells (which secrete GLP-1). This led to speculation that TCF7L2 confers risk of diabetes via changes in circulating GLP-1. This has turned out to not be the case. This raises the possibility that these diabetogenic effects are mediated via an inability of islet GLP-1 to adapt to rising glycemia. Therefore, this experiment will determine the contribution of islet GLP-1 to the functional abnormalities of the islet associated with the TCF7L2 locus.",[28,393],"Type2diabetes",[395],"TCF7L2","2026-01-28",{"date":398,"type":40},"2026-01-30",{"date":400,"type":22},"2026-10-01",{"date":402,"type":22},"2029-03-01",{"name":404,"class":74},"Mayo Clinic",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":411,"targetDuration":412,"studyType":23,"phases":4,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":48},"100410114","genetic-investigation-of-cancer-predisposition-100410114","NCT04620278","Genetic Investigation of Cancer Predisposition","Inclusion Criteria:\n\n1. Any age\n2. Meets at least ONE of the following:\n\n   1. Personal history (with documented diagnosis) of cancer before the age of 50\n   2. Personal history of more than one primary cancer\n   3. Documented diagnosis of cancer AND family history of that same cancer type or multiple other cancers that do not fit classical criteria of hereditary cancer syndromes\n   4. Documented diagnosis of a rare cancer AND family history of rare cancers that do not fit classical criteria of hereditary cancer syndromes\n   5. There is the same type of cancer in several generations of a family\n   6. Documented diagnosis of multicentric cancers (e.g bilateral cancers in paired organs, or multifocal cancers in single organs) that usually occur as single lesions when presented sporadically\n   7. Early onset cancer (before the age of 50, or breast cancer before age 45) AND family history of early onset cancer Capable of providing access to detailed medical records and family history of cancer\n\nExclusion Criteria:\n\n1. Established genetic diagnosis of a known hereditary cancer syndrome that is compatible with the clinical presentation\n2. Incarcerated",{"count":356,"type":22},"60 Months","Clinical information and samples (blood, saliva, and tumor) will be collected from patients with multiple cancers and\u002For a family history of cancer as well as from affected and unaffected relatives; samples will be systematically sequenced and evaluated for candidate driver mutations.",[28,308],[416,417],"Genetic analysis","Early diagnosis","2026-01-02",{"date":420,"type":40},"2026-01-06",{"date":422,"type":22},"2026-10",{"date":424,"type":22},"2035-12",{"name":426,"class":74},"The University of Texas Health Science Center at San Antonio",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":435,"minAge":436,"maxAge":386,"enrollmentInfo":437,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":439,"conditions":440,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":48},"100421095","precision-medicine-in-the-prostate-cancer-care-pathway-100421095","NCT04763317","Precision Medicine in the Prostate Cancer Care Pathway","Precision Medicine in the Prostate Cancer Care Pathway: an Evaluation of Integrating Germline Genetic Testing Into the Management of Men at Risk of \u002F Living With Prostate Cancer","PMPRC","Inclusion Criteria:\n\nAffected cohort:\n\n1. Affected with PrCa \\\u003C 60 years or\n2. Affected with metastatic castration resistant PrCa (mCRPC) at any age or Aggressive PrCa Gleason 4+4 or higher \\\u003C70 years\n3. Affected with family history defined as three or more cases any age (FDR or SDR)\n\nUnaffected cohort: (This cohort is no longer recruiting, it has completed recruitment)\n\nAged \\>30 and with a family history defined as:\n\n1. FDR diagnosed \\\u003C 70\n2. 2 or more cases in First or Second Degree Relatives (FDR\u002FSDR) with one case diagnosed \\\u003C 70 years\n3. 3 or more cases at any age (on same side of family)\n\nExclusion Criteria:\n\n* • WHO performance status 4","MALE","30 Years",{"count":438,"type":22},3000,"This study aims to evaluate the use of a prostate cancer specific predisposition genetic panel test in men with \u002F at high risk of prostate cancer. The genetic test will analyse men's DNA samples for the presence of mutations in rare genes as well as common genetic variation to provide men with information about their risk of prostate cancer. This study will evaluate the clinical impact of the test on risk assessment and clinical management in terms of screening and treatment.",[441,28],"Prostate Cancer","2025-12-08",{"date":444,"type":40},"2025-12-16",{"date":446,"type":40},"2019-02-14",{"date":448,"type":22},"2034-12",{"name":450,"class":74},"Institute of Cancer Research, United Kingdom",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":88,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":477},"100349358","ptx3-targeted-antifungal-prophylaxis-100349358","NCT03828773","PTX3-targeted Antifungal Prophylaxis","PTX3 Genetically Stratified Randomized Double-blinded Allocation Event-driven Clinical Trial for Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia","PTX3AML","Inclusion Criteria:\n\n1. Signed Informed Consent according to national\u002Flocal regulations.\n2. Age ≥18 years.\n3. Diagnosis of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome in transformation (MDSit) treated with an intensive chemotherapy regimen, including induction \u002F consolidation \u002F salvage remission chemotherapy.\n4. Planned hospital admission for the duration of the neutropenic phase (absolute neutrophils count \\\u003C500 cells\u002Fmm3).\n\nExclusion Criteria:\n\n1. Patients with neutropenia (absolute neutrophils count\\\u003C500 cells\u002Fmm3) upon presentation and prior to chemotherapy initiation.\n2. Patients with a diagnosis of acute promyelocytic leukemia (APL) or AML-M3.\n3. Patients with known history of allergy, hypersensitivity or serious reaction to azole antifungals\n4. Women who are pregnant (positive blood\u002Furine pregnancy test within 10 days before randomization) or breast-feeding.\n5. Diagnosis and treatment for an Invasive Fungal Infection (IFI) within 3 months prior to study enrolment and an Invasive Mold Infection (IMI) at any point prior to or at the time of enrolment.\n6. Severe liver dysfunction, defined as at least one of the following markers: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or alkaline phosphatase above \\>5x upper limit of normality: and\u002For total bilirubin above \\>3x upper limit of normality.\n7. Patients with an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.\n8. Patients who are receiving and cannot discontinue the following drugs at least 24 hours prior to randomization: terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine (because of the possibility of QT prolongation), sirolimus, rifampin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital, mephobarbital), ritonavir, efavirenz, or ergot alkaloids (e.g., ergotamine, dihydroergotamine).\n9. Serious uncontrolled concomitant disease or comorbidity that, in the opinion of the investigator, may compromise adherence to the study protocol.\n10. Receipt of a prior allogeneic Hematopoietic Cell Transplantation (HCT).\n11. Previous exposure to mold-active prophylaxis (\\>48 hours within 7 days of inclusion).\n12. Patients with relapsed leukemia already included in the trial.\n13. Patient not affiliated to the French social security system\n14. Patient under legal protection (guardianship, curatorship)",{"count":460,"type":22},410,[148],"This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute myeloid leukemia who receive induction chemotherapy. Allocation strategy based on an invasive mold infection genetic risk will be double-blinded.",[464,465,466,28,467],"Candidiasis","Fungal Infection","Acute Myeloid Leukemia","Aspergillosis","2025-12-02",{"date":470,"type":40},"2025-12-09",{"date":472,"type":40},"2019-02-11",{"date":474,"type":22},"2027-11-30",{"name":476,"class":74},"Bochud Pierre-Yves",9,{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":485,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":88,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":48},"100613869","understanding-gene-environment-interaction-in-alcohol-related-hepatocellular-carcinoma-100613869","NCT07272200","Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma","GENIAL","Inclusion Criteria:\n\nPatients from the EPIDEMIC (approval no. 1822 of 27 August 2013) and SERENA (last amendment no. 1151\\_2021 of 9 November 2021), already approved by the CE Milano Area 2 will be included.\n\n* Diagnosis of NAFLD or cryptogenic liver disease, allowing a more liberal alcohol intake limit (\\\u003C60\u002F40 g\u002Fday in M\u002FF), so that subjects with a moderate alcoholic component of the hepatopathy are also included, Important factor given the high epidemiological weight of this group\n* Any of the following:\n* Male patient with type 2 diabetes or obesity carrying at least three genetic variants in PNPLA3, TM6SF2, MBOAT7.\n* Willingness to sign informed consent.\n\nExclusion Criteria:\n\n* Alcohol intake \\>60\u002F40 g\u002Fday in M\u002FF\n* Chronic viral or autoimmune hepatitis\n* Any previously diagnosed liver genetic disease associated with increased risk of HCC (such as hereditary hemochromatosis, Wilson's disease, Alpha-1 antitrypsin deficiency)\n* Use of drugs known to induce steatosis and liver disease\n* HCC previously diagnosed the study start date.\n* Other pathological conditions with prognosis less than two years.","45 Years","75 Years",{"count":21,"type":22},[148],"It has been estimated that alcohol causes around 40% of premature liver deaths in Europe each year, although this number is probably underestimated. Alcohol-related liver disease (ALD) is the most common cause of liver cirrhosis and liver death in Europe with a peak age of deaths occurring among individuals aged 40 to 50. Despite these findings, ALD is little studied with only 5% of all clinical trials in the field of liver disease recorded on ClinicalTrials.gov and only 5% of all publications in the same research area.\n\nLiver cancer is the second most common cause of cancer-related death (15-20% survival at 5 years) and the second most common cause of alcohol-related cancers worldwide.\n\nLike other complex diseases, ALD-HCC results from the interaction between environmental determinants and genetic variations but knowledge of gene-environment interactions is currently lacking in this area. The GENIAL project will address these needs through a comprehensive evaluation of gene-environment interactions concerning ALD-HCC.",[491,28],"HCC","2025-11-26",{"date":470,"type":40},{"date":495,"type":40},"2023-12-01",{"date":497,"type":22},"2028-12-31",{"name":499,"class":74},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":485,"maxAge":486,"enrollmentInfo":508,"targetDuration":4,"studyType":88,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":48},"100556290","evaluation-of-risk-of-hepatocellular-carcinoma-100556290","NCT06523179","Evaluation of Risk of hEpatocellular Carcinoma","Study for the Evaluation of Risk of hEpatocellular Carcinoma in NonAlcoholic Fatty Liver","PERSPECTIVE","Inclusion Criteria:\n\n* Diagnosis of NAFLD or cryptogenic liver disease, allowing a more liberal alcohol intake limit (\\\u003C60\u002F40 g\u002Fday in M\u002FF), so as to also include subjects with a moderate alcoholic component of liver disease, an important factor given the high epidemiological burden of this group\n* Age between 45 and 75 years\n* Any of the following criteria:\n* F3-F4 fibrosis, determined histologically, or by non-invasive techniques (stiffness \\> 7.9 kPa at Fibroscan and positivity at the NAFLD fibrosis score or at APRI or at FIB4), or evidence of cirrhosis deriving from biochemical tests or imaging methods;\n* Family history of primary liver cancer in first degree parentage, or carrier status of rare mutations associated with the development of HCC (such as mutations in APOB and TERT)\n* Male patient with type 2 diabetes or obesity carrying at least three genetic variants in PNPLA3, TM6SF2, MBOAT7.\n* Willingness to sign the informed consent.\n\nExclusion Criteria:\n\n* Alcohol intake \\>60\u002F40 g\u002Fday in M\u002FF\n* Chronic viral or autoimmune hepatitis\n* Any previously diagnosed genetic liver disease associated with increased risk of HCC (such as hereditary hemochromatosis, Wilson's disease, Alpha-1 Antitrypsin deficiency)\n* Use of drugs known to induce steatosis and liver disease\n* HCC diagnosed before the study start date.\n* Other pathological conditions with a prognosis of less than two years.",{"count":509,"type":22},500,[148],"Hepatocellular carcinoma (HCC) is the fifth most common solid cancer and the second cause of cancer-related mortality worldwide. Nonalcoholic fatty liver disease (NAFLD), that is hepatic accumulation of fat in excess of 5% not explained by at risk alcohol intake, is projected to become the leading cause of HCC in Western countries within 2025.NAFLD is most frequently caused by insulin resistance due to unhealthy lifestyle. Due to the epidemics of obesity and type 2 diabetes, NAFLD now affects one in three individuals worldwide.\n\nNAFLD-HCC frequently develops without overt cirrhosis suggesting that steatosis directly promotes hepatic carcinogenesis.",[513,491,28],"NASH","2025-11-17",{"date":516,"type":40},"2025-11-20",{"date":518,"type":40},"2018-01-01",{"date":520,"type":22},"2035-12-31",{"name":499,"class":74},{"id":523,"slug":524,"hasResults":12,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":435,"minAge":56,"maxAge":4,"enrollmentInfo":530,"targetDuration":84,"studyType":23,"phases":4,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":48},"100566779","prostate-tissue-biobank-100566779","NCT06659614","Prostate Tissue BioBank","Prostate Tissue Biobank for People at Genetic Risk for Aggressive Disease","PTBB","Inclusion Criteria:\n\nCarriers (Group 1):\n\n1. Confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene.\n2. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer\n\nControls (Group 2):\n\n1\\. Patients undergoing prostate biopsies as a part of their prostate cancer screening OR biopsy or prostatectomy due to a diagnosis of prostate cancer\n\nExclusion Criteria:\n\n* N\u002FA",{"count":531,"type":22},200,"Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1\u002F2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13. The investigators have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation.\n\nThe Prostate Tissue BioBank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline DNA from pathogenic mutation carriers in addition to age-matched control samples. Our primary goal is to investigate prostate cancer development and treatment response in carriers of germline DNA repair mutations, as compared to non-carrier controls.",[441,28],"2025-11-04",{"date":536,"type":40},"2025-11-05",{"date":538,"type":40},"2024-01-01",{"date":540,"type":22},"2034-01",{"name":542,"class":74},"Abramson Cancer Center at Penn Medicine",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":88,"phases":552,"briefSummary":553,"conditions":554,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":48},"100522961","genetic-information-assistant-in-telegenetics-100522961","NCT06089421","Genetic Information Assistant in Telegenetics","A Prospective, Randomized Trial to Compare Telegenetics to Counseling Via a Novel Genetic Information Assistant in High-risk Cancer Patients.","Inclusion Criteria:\n\n* At high risk for having a genetic pathogenic variant as assessed by a GC or physician according to the NCCN guidelines\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, aged 18 and over.\n* Subjects must have a smartphone with access to cellular and\u002For internet service or a computer with internet service.\n* Subjects must have technological competency\u002Fproficiency to use their Smartphone and\u002For computer in conjunction with the communication aid GIA.\n\nExclusion Criteria:\n\n* Cannot communicate in English or Spanish.\n* Subjects must not have completed panel-based cancer genetic testing in the past.",{"count":551,"type":22},96,[148],"The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is:\n\n• Does receiving pre-genetic test education with a chat bot or genetic counselor affect if the participant decides to get genetic testing?\n\nParticipants will:\n\n* have a pre-test genetic counselling session with a genetic counselor or the GIA chatbot\n* answer questions about their cancer genetic knowledge and how they are doing\n* provide a saliva sample for genetic testing to test for cancer gene mutations\n* have their genetic testing results provided to them.\n* have the option to share their genetic testing results with family members\n\nResearchers will compare how many participants who had pre-genetic counseling with the chatbot received genetic testing to how many participants who had pre-genetic counseling with a genetic counselor received genetic testing.",[151,28],"2025-09-17",{"date":557,"type":40},"2025-09-23",{"date":559,"type":40},"2025-04-01",{"date":561,"type":22},"2027-08-01",{"name":563,"class":74},"University of Virginia",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":572,"maxAge":56,"enrollmentInfo":573,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":589},"100510710","international-childhood-leukemia-microbiomemetabolome-cohort-100510710","NCT05929976","InterNatIonal CHildhood Leukemia Microbiome\u002FMEtabolome Cohort","Multi-National Nutritional Biobanking Program in Pediatric Oncology InterNatIonal CHildhood Leukemia Microbiome\u002FMEtabolome Cohort","NICHE","Inclusion Criteria:\n\n* Patients must be between 3 years and 18 years of age at time of assent\u002Fconsent.\n* Patients must have newly diagnosed B- or T-cell ALL, or mixed phenotype acute leukemia confirmed by pathology report.\n* Patients must be receiving treatment at one of the participating centers.\n\nExclusion Criteria:\n\n\\- Patients receiving hematopoietic cell transplant.","3 Years",{"count":574,"type":22},4900,"Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create a biobank of clinical data and biological specimens which will foster future studies on cancer progression and prognosis as well as toxicities during treatment which may impact survivorship and late-effects. Eligible patients must be between 3 years and 18 years of age at time of assent\u002Fconsent, have newly diagnosed B- or T-cell acute lymphoblastic leukemia or mixed phenotype acute leukemia confirmed by pathology report, and must be receiving treatment at one of the participating centers. Patients receiving hematopoietic cell transplant will be excluded. Institutions were selected to ensure representation of several global health indicators related to nutritional status and wealth classification according to the World Bank. Data related to demographic variables (socioeconomic status, food security), lifestyle habits (diet, physical activity), nutritional anthropometrics (height, weight and arm anthropometry), and nutritional biological indices (stool and blood) will be collected at designated timepoints throughout treatment and one year after the end of treatment.",[577,578,579,28],"Acute Lymphoblastic Leukemia","Nutrition Aspect of Cancer","Microtia","2025-07-17",{"date":582,"type":40},"2025-07-22",{"date":584,"type":40},"2022-10-26",{"date":586,"type":22},"2029-10-01",{"name":588,"class":74},"Columbia University",8,{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":88,"phases":598,"briefSummary":599,"conditions":600,"keywords":610,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":48},"100545064","using-the-ehr-to-advance-genomic-medicine-across-a-diverse-health-system-100545064","NCT06377033","Using the EHR to Advance Genomic Medicine Across a Diverse Health System","Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System","Inclusion Criteria:\n\n* 18 years of age or older\n* diagnosed with one of the study conditions\n\nExclusion Criteria:\n\n* Under 18 years of age\n* not diagnosed with one of the study conditions",{"count":21,"type":22},[148],"Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place.\n\nInnovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and\u002For patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management.",[28,601,602,603,604,605,606,607,608,609],"Paraganglioma","Pheochromocytoma","ALS","Parkinson Disease","Polyneuropathies","Frontotemporal Dementia","Alzheimer Disease","Cardiomyopathy Non-ischemic","Thoracic Aortic Aneurysm",[611,612,613],"Genetic testing","Genomic medicine","Electronic health record","2025-07-16",{"date":616,"type":40},"2025-07-20",{"date":618,"type":40},"2024-06-10",{"date":620,"type":22},"2027-06-30",{"name":622,"class":74},"University of Pennsylvania",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":631,"conditions":632,"keywords":636,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":645},"100484392","investigating-hereditary-risk-in-thoracic-cancers-inherit-100484392","NCT05587439","Investigating Hereditary Risk In Thoracic Cancers (INHERIT)","INHERIT","Inclusion Criteria:\n\n* Cohort 1: individuals with or with high risk of carrying an EGFR T790M or other EGFR germline variant identified in blood or saliva, including via somatic single or multi-gene panel testing (MGPT). This includes both probands and family members.\n\n  * Participants with variants of uncertain significance may be eligible at the PI's discretion\n* Cohort 2: individuals with or with high risk of carrying non-EGFR germline variants suggestive of a potential inherited lung cancer risk, identified in blood or saliva, including via somatic single or multi-gene panel testing (MGPT). This includes both probands and family members.\n\n  * Participants with variants of uncertain significance may be eligible at the PI's discretion\n* Cohort 3: individuals with lung cancer who are not known to carry a pathogenic or likely pathogenic variant, and with one of the following:\n\n  * first-degree relative with lung cancer\n  * multi-generational family history of lung cancer\n  * personal history of multiple primary lung cancers or other neoplasms\n  * multifocal lung cancer This includes both probands and their families.\n* For each cohort, the following applies:\n\n  * May include blood relatives of individuals with the aforementioned variants or family history, who may be presumed obligate carriers or healthy controls\n  * Deceased patients may be included in the study. Pathology specimens and public records, such as death certificates, may be used to confirm information. If medical records and\u002For pathology specimens are needed, consent will be obtained from the descendant's next-of-kin. Next-of-kin refers to the following hierarchy of relatives: spouse, offspring, parents, and siblings. (Any further use of \"next-of-kin\" in this protocol refers to this hierarchy).\n  * Data and specimens from previously consented eligible individuals (under Dana-Farber IRB protocol #12-360) will also be deposited into the study database and specimen banks from other investigators as long as their consents permit sharing of specimens and data. It is estimated that approximately 150 individuals may qualify under these criteria.\n  * Some of the variants identified initially through germline testing may ultimately be shown to not be germline but rather somatic mosaic (ACE or CHIP). These individuals will remain in the study cohort but will not be asked for ongoing questionnaire or repeat specimen donation\n\nExclusion Criteria:\n\n* Individuals who decline to consent\n* Individuals who are unable to give consent or assent and are without a designated healthcare proxy",{"count":509,"type":22},"The purpose of this research study is to learn more about the inherited risk for developing lung cancer.",[633,634,28,635],"Lung Cancer","Genetic Disease","Hereditary Diseases",[633,634,28,635],"2025-07-07",{"date":639,"type":40},"2025-07-10",{"date":641,"type":40},"2023-01-01",{"date":643,"type":22},"2027-11-01",{"name":271,"class":74},2,{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":653,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":88,"phases":656,"briefSummary":657,"conditions":658,"keywords":668,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":645},"100592416","slow-speed-slowing-parkinsons-early-through-exercise-dosage-100592416","NCT06993142","Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage","Slow-SPEED","Inclusion criteria\n\n1. previously identified LRRK2 G2019S or GBA N370S variant based on genotyping\n2. aged 50 years or older\n3. able to understand the English language\n4. being able to walk independently inside the home without the use of a walking aid\n5. in possession of a suitable smartphone (screen size minimum 4.6 inch), (Android version 9 or iOS version 15 or newer)\n6. Not in a high physical activity range during the 4-week eligibility and baseline period\n\nExclusion criteria\n\n1. clinically diagnosed or self-reported diagnosis neurodegenerative disease\n2. self-reported falls of three or more per year\n3. dexterity problems or cognitive impairments hampering smartphone use\n4. if they are not aware of and do not wish to be informed about an increased risk of developing diseases associated with the LRRK2 or GBA1 risk variant\n5. if individual is not community-dwelling\n6. in possession of one of the following devices: Huawei P8 Lite; Huawei P9 Lite; Xiaomi Mi 6; Huawei P20 Lite (Fitbit is incompatible)","50 Years",{"count":655,"type":22},600,[148],"The goal of this clinical trial is two-fold. First to investigate the feasibility of whether a remotely administered smartphone app can increase the volume and intensity of physical activity in daily life in individuals with a LRRK2 G2019S or GBA1 N370S genetic mutation over a long period of time (24 months). Second, to explore the preliminary efficacy of exercise on markers for prodromal Parkinson's disease progression in individuals with a LRRK2 G2019S or GBA1 N370S genetic mutation.\n\nParticipants will be tasked to achieve an incremental increase of daily steps (volume) and amount of minutes exercised at a certain heart rate (intensity) with respect to their own baseline level. Motivation with regards to physical activity will entirely be communicated through the study specific Slow Speed smartphone app. A joint primary objective consists of two components. First to determine the longitudinal effect of an exercise intervention in LRRK2 G2019S or GBA1 N370S variant carriers on a prodromal load score, comprised of digital biomarkers of prodromal symptoms. The secondary component of the primary outcome is to determine the feasibility of a remote intervention study. The secondary objective is the effect of a physical activity intervention on digital markers of physical fitness. Exploratory outcomes entail retention rate, completeness of remote digital biomarker assessments, digital prodromal motor and non-motor features of PD. Using these biomarkers, the investigators aim to develop a composite score (prodromal load score) to estimate the total prodromal load. An international exercise study with fellow researchers in the United Kingdom are currently in preparation (Slow-SPEED-UK) and active in the Netherlands (Slow-SPEED-NL). Our intention is to analyse overlapping outcomes combined where possible through a meta-analysis plan, to obtain insight on (determinants of) heterogeneity in compliance and possible efficacy across subgroups",[604,659,660,661,662,663,664,665,666,667,28],"Prodromal Stage","Neurodegenerative Diseases","Basal Ganglia Diseases","Central Nervous System Diseases","Synucleinopathies","Nervous System Diseases","Cerebral Disorder","Brain Diseases","Parkinsonian Disorders",[669,670,671,672,673,674,675,676,677,604,678,679,680,365,681],"Physical activity","Prevention","Remote","Mobile Health (mHealth)","Feasibility","Exercise","Digital biomarker","Motivational application","Walking","Prodromal","LRRK2","GBA1","Smartwatch","2025-05-28",{"date":684,"type":40},"2025-06-03",{"date":686,"type":22},"2025-07-01",{"date":688,"type":22},"2029-06-30",{"name":690,"class":74},"Radboud University Medical Center"]